Health Blueprint

Back to Longevity News

News summary

AcuraStem Receives Hoffman ALS Clinical Trial Award to Support Phase 1 Trial of AS-241, the Clinical Candidate of its UNC13A Program

Source: BioSpace - Funding • Published: 28 Oct 2026, 01:15

Summarized by Masters of Longevity from BioSpace - Funding.

A $1 million award will fund biomarker development for AS-241 Phase 1 testing.

AcuraStem Receives Hoffman ALS Clinical Trial Award to Support Phase 1 Trial of AS-241, the Clinical Candidate of its UNC13A Program
Key Takeaways
  • The award is funding biomarker work for AS-241 Phase 1.
  • AS-241 is an antisense oligonucleotide to correct UNC13A splicing.
  • Preclinical studies showed AS-241 restored UNC13A and improved neurons.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.